Comparing blood thinners for people with cirrhosis and portal vein clots
Official title: Efficacy and Safety of Anticoagulant Therapy for Portal Vein Thrombosis In Cirrhosis Patients With and Without Hepatocellular Carcinoma
Run by Mansoura University · NCT07132515 · Data updated 2026-11-12
This will try enoxaparin, warfarin, or apixaban in people with cirrhosis and portal vein thrombosis (with or without liver cancer) to see which controls the clot and is safest.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Mansoura University Academic / other |
| Locations | 1 site (Al Mansurah, Dakahlia Governorate) |
| Status | Recruiting |
| Started | August 15, 2023 |
| Main results expected | August 2025 |
| Study ends | August 2025 |
| Registry record updated | August 20, 2025 |
| Trial ID | NCT07132515 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with cirrhosis (Child‑Pugh A or B) and portal vein thrombosis, with or without hepatocellular carcinoma, who do not have severe renal failure, extremely low platelets, active uncontrolled bleeding, or Budd‑Chiari syndrome.
✕Probably not a fit
Patients with creatinine >1.9 mg/dL, platelets <10,000, uncontrolled active bleeding, or Budd‑Chiari syndrome are excluded and unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with cirrhosis (Child‑Pugh A or B) who have portal vein thrombosis, with or without hepatocellular carcinoma, will receive one of three anticoagulants (enoxaparin, warfarin, or apixaban) and be followed over time. The study will monitor clot resolution, bleeding complications, and other safety outcomes while excluding those with very low platelets, significant renal impairment, Budd‑Chiari syndrome, or uncontrolled active bleeding. As a Phase 4 interventional trial at Mansoura University Hospitals, it compares drugs already in clinical use rather than testing a new agent. Imaging and laboratory follow-up will be used to detect recanalization and adverse events.
Why it matters
Potential benefit: If successful, the results could clarify which commonly used blood thinner offers the best balance of clot resolution and safety for patients with cirrhosis and portal vein thrombosis.
How similar studies have gone: Previous studies have shown that anticoagulation can promote recanalization of portal vein thrombosis in cirrhosis and reduce progression, and emerging data suggest direct oral anticoagulants like apixaban may be effective but are less extensively studied than heparins or warfarin.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Portal vein thrombosis, Cirrhosis, With or without HCC, Child A \& B Exclusion Criteria: * Platelets\<10000, Createnine \>1.9, Budd ciarri, Uncontrolled active bleeding
Where it's running
-
Mansoura University Hospitals
Al Mansurah, Dakahlia Governorate, Egypt Recruiting
Study contacts
- Study coordinator: Dalia Elsayed Ganady, MBBS
- Email: dalia.tawfik97@gmail.com
- Phone: +201095529264
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Apixaban plus carvedilol to prevent portal-hypertension complications in cirrhosis
This will test whether adding apixaban to carvedilol can help prevent variceal bleeding, portal vein thrombosis, and other portal-hypertension complications in adults with Child-Pugh B cirrhosis.
-
Factors that affect reopening of blocked portal veins in people with cirrhosis and gastroesophageal varices
This project looks at past records and follow-up to see which factors are linked with reopening (recanalization) of blocked portal veins in people who have cirrhosis and endoscopy-confirmed gastroesophageal varices.
-
Apixaban for portal vein clots that appear more than a year after laparoscopic splenectomy
This trial tests whether taking apixaban twice daily can treat portal vein blood clots that develop more than a year after laparoscopic splenectomy in people with cirrhosis.
-
Apixaban for portal vein thrombosis occurring more than one year after laparoscopic splenectomy and azygoportal disconnection
This trial will try whether taking apixaban 2.5 mg twice daily can treat portal vein clots that appear more than a year after laparoscopic splenectomy and azygoportal disconnection in people with cirrhosis.
-
Non-invasive tests to predict outcomes after curative treatment for hepatocellular carcinoma
This project will test whether regular non-invasive liver and spleen stiffness checks plus scheduled endoscopies can help predict future complications in people with compensated chronic liver disease who receive curative-intent treatment for HCC.
-
Observational cohort for non-alcoholic fatty liver disease and related conditions
This study is trying to learn more about non-alcoholic fatty liver disease and its related conditions by looking at patients with different stages of the disease and comparing them to people with diabetes and obesity who don't have it.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.